The Singapore Eye Research Institute (SERI) has achieved a significant milestone by ranking first among non-academic institutes in ophthalmology on the American scholarly analytics platform ScholarGPS. This accomplishment, announced in December 2025, also places SERI second overall among all institutes globally in the field, based on data from the past five years.
SERI’s rise in the rankings underscores its longstanding commitment to advancing ophthalmic research and biopharmaceuticals. Since its establishment in 1997, the institute has been pivotal in positioning Singapore as a hub for medical research and innovation in the Asia-Pacific region. ScholarGPS evaluates institutions on metrics such as research output and citation impact, and SERI’s performance reflects its dedication to cutting-edge research and clinical excellence.
Key areas of SERI’s research include diabetic retinopathy, myopia, and glaucoma, with newer ventures into artificial intelligence and digital health. Executive Director Jodhbir Mehta stated, “This milestone is a testament to the dedication and expertise of our research teams, clinician-scientists, and support staff who have worked tirelessly to advance the frontiers of ophthalmology research.”
SERI’s translational research has led to tangible patient benefits, such as the development of Vabysmo, a treatment reducing injection frequency for diabetic eye diseases, and Myopine, an eye drop for childhood myopia. The institute has also pioneered devices like the EndoGlide for corneal transplants and the Singapore Eye Lesion Analyser (SELENA+), an AI tool for detecting diabetes-related eye diseases.
As SERI continues to build on its achievements, it remains at the forefront of integrating innovative research into practical applications, enhancing patient outcomes globally.
